Characteristics of the patients at diagnosis: standard intensity PII versus increased intensity PII
| Characteristic* . | STD therapy, no. (%), N = 649 . | Increased intensity PII, no. (%), N = 650 . | P, t . |
|---|---|---|---|
| Age, y | .42 | ||
| 1 to 9 | 249 (38.4) | 229 (35.2) | — |
| 10 to 15 | 324 (49.9) | 334 (51.4) | — |
| Over 16 | 76 (11.7) | 87 (13.4) | — |
| White cells, × 103/ | .52 | ||
| Less than 50 | 321 (49.8) | 337 (52.1) | — |
| 50 to 199 | 260 (38.8) | 241 (37.2) | — |
| More than 200 | 64 (9.9) | 69 (10.7) | — |
| Sex | .15 | ||
| Male | 392 (60.4) | 366 (56.3) | — |
| Female | 257 (39.6) | 284 (43.7) | — |
| Race | .57 | ||
| White | 454 (70.9) | 439 (68.7) | — |
| Black | 36 (5.6) | 34 (5.3) | — |
| Other | 150 (23.4) | 166 (26) | — |
| Liver† | .49 | ||
| Normal | 211 (48.6) | 199 (45.6) | — |
| Moderately enlarged | 189 (43.5) | 207 (47.5) | — |
| Markedly enlarged | 30 (6.9) | 34 (7.8) | — |
| Spleen | .76 | ||
| Normal | 267 (41.8) | 267 (41.3) | — |
| Moderately enlarged | 300 (46.6) | 311 (48.1) | — |
| Markedly enlarged | 68 (10.5) | 75 (11.6) | — |
| Lymph nodes | .39 | ||
| Normal | 292 (45.3) | 317 (49.0) | — |
| Moderately enlarged | 294 (45.7) | 279 (43.1) | — |
| Significantly enlarged | 58 (9.0) | 51 (7.9) | — |
| Mediastinal mass | .39 | ||
| Absent | 536 (83.4) | 549 (85.1) | — |
| Present | 96 (14.9) | 107 (16.6) | — |
| Hemoglobin (g/dL) | .17 | ||
| 1 to 7.9 | 304 (48.3) | 271 (43.6) | — |
| 8.0 to 10.9 | 193 (30.6) | 195 (31.4) | — |
| More than 11.0 | 133 (21.1) | 155 (25.0) | — |
| Platelets, × 103/ | .17 | ||
| 1 to 49 | 347 (53.5) | 346 (53.2) | — |
| 50 to 149 | 221 (34.1) | 201 (30.9) | — |
| More than 150 | 81 (12.5) | 103 (15.8) | — |
| Immunophenotyping | .39 | ||
| B-cell lineage | 430 (79.2) | 449 (80.0) | — |
| T-cell lineage | 123 (22.7) | 112 (20.0) | — |
| Karyotypic features‡ | |||
| No. | .77 | ||
| Diploid (46) | 114 (32.6) | 107 (31.5) | — |
| Pseudodiploid (46) | 109 (31.1) | 121 (35.6) | — |
| Hypodiploid (less than 46) | 33 (9.4) | 34 (10.0) | — |
| Hyperdiploid (47 to 50) | 44 (12.6) | 36 (10.6) | — |
| Hyperdiploid (more than 50) | 50 (14.3) | 42 (12.4) | — |
| Translocations | |||
| t(4; 11) present | 7 (2) | 9 (2.6) | .57 |
| t(4; 11) absent | 343 (98) | 331 (97.4) | — |
| t(1; 19) present | 16 (4.6) | 19 (5.6) | .54 |
| t(1; 19) absent | 334 (95.4) | 321 (94.4) | — |
| Characteristic* . | STD therapy, no. (%), N = 649 . | Increased intensity PII, no. (%), N = 650 . | P, t . |
|---|---|---|---|
| Age, y | .42 | ||
| 1 to 9 | 249 (38.4) | 229 (35.2) | — |
| 10 to 15 | 324 (49.9) | 334 (51.4) | — |
| Over 16 | 76 (11.7) | 87 (13.4) | — |
| White cells, × 103/ | .52 | ||
| Less than 50 | 321 (49.8) | 337 (52.1) | — |
| 50 to 199 | 260 (38.8) | 241 (37.2) | — |
| More than 200 | 64 (9.9) | 69 (10.7) | — |
| Sex | .15 | ||
| Male | 392 (60.4) | 366 (56.3) | — |
| Female | 257 (39.6) | 284 (43.7) | — |
| Race | .57 | ||
| White | 454 (70.9) | 439 (68.7) | — |
| Black | 36 (5.6) | 34 (5.3) | — |
| Other | 150 (23.4) | 166 (26) | — |
| Liver† | .49 | ||
| Normal | 211 (48.6) | 199 (45.6) | — |
| Moderately enlarged | 189 (43.5) | 207 (47.5) | — |
| Markedly enlarged | 30 (6.9) | 34 (7.8) | — |
| Spleen | .76 | ||
| Normal | 267 (41.8) | 267 (41.3) | — |
| Moderately enlarged | 300 (46.6) | 311 (48.1) | — |
| Markedly enlarged | 68 (10.5) | 75 (11.6) | — |
| Lymph nodes | .39 | ||
| Normal | 292 (45.3) | 317 (49.0) | — |
| Moderately enlarged | 294 (45.7) | 279 (43.1) | — |
| Significantly enlarged | 58 (9.0) | 51 (7.9) | — |
| Mediastinal mass | .39 | ||
| Absent | 536 (83.4) | 549 (85.1) | — |
| Present | 96 (14.9) | 107 (16.6) | — |
| Hemoglobin (g/dL) | .17 | ||
| 1 to 7.9 | 304 (48.3) | 271 (43.6) | — |
| 8.0 to 10.9 | 193 (30.6) | 195 (31.4) | — |
| More than 11.0 | 133 (21.1) | 155 (25.0) | — |
| Platelets, × 103/ | .17 | ||
| 1 to 49 | 347 (53.5) | 346 (53.2) | — |
| 50 to 149 | 221 (34.1) | 201 (30.9) | — |
| More than 150 | 81 (12.5) | 103 (15.8) | — |
| Immunophenotyping | .39 | ||
| B-cell lineage | 430 (79.2) | 449 (80.0) | — |
| T-cell lineage | 123 (22.7) | 112 (20.0) | — |
| Karyotypic features‡ | |||
| No. | .77 | ||
| Diploid (46) | 114 (32.6) | 107 (31.5) | — |
| Pseudodiploid (46) | 109 (31.1) | 121 (35.6) | — |
| Hypodiploid (less than 46) | 33 (9.4) | 34 (10.0) | — |
| Hyperdiploid (47 to 50) | 44 (12.6) | 36 (10.6) | — |
| Hyperdiploid (more than 50) | 50 (14.3) | 42 (12.4) | — |
| Translocations | |||
| t(4; 11) present | 7 (2) | 9 (2.6) | .57 |
| t(4; 11) absent | 343 (98) | 331 (97.4) | — |
| t(1; 19) present | 16 (4.6) | 19 (5.6) | .54 |
| t(1; 19) absent | 334 (95.4) | 321 (94.4) | — |
The global χ 2 test for homogeneity was used.
— indicates not applicable.
Because of rounding, not all percentages total 100. Percentages were based on the number of patients for whom there were data on the various characteristics.
The degree of organomegaly was determined as described by Steinherz et al.11
The centrally reviewed and accepted cytogenetic data were available for a subgroup of patients.